GlaxoSmithKline - Company Profile

The publisher explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot

Overview - GlaxoSmithKline’s sales will grow steadily through to 2026 due to new launches.

Key themes - [1] Shingrix’s rapid growth will not be repeated over the coming years as GlaxoSmithKline is capacity-constrained until 2024 [2] Expansion into oncology with Zejula, belantamab mafodotin, dostarlimab, and bintrafusp alfa [3] HIV franchise in transition phase as market moves away from triple products to newer two-drug regimens like Dovato and cabotegravir + rilpivirine [4] Eventual IPO of the GlaxoSmithKline and Pfizer Consumer Healthcare Joint Venture will provide GSK with significant capital to potentially pursue M&A.

Model updates (3 August 2020)

• Cabotegravir forecast added after recent results from Phase III studies in HIV prophylaxis
• Infanrix/Pediarix forecast adjusted lower due to impact from COVID-19
• Hepatitis vaccines forecast adjusted lower due to impact from COVID-19
• Boostrix forecast adjusted lower due to impact from COVID-19.

Model updates (1 June 2020)

• Juluca forecast adjusted lower.

Model updates (28 February 2020)

• Shingrix forecast adjusted higher to account for more robust sales and significant capacity increase in 2024
• Tivicay forecast adjusted lower due to competitive trends in the HIV market
• Triumeq forecast adjusted lower due to competitive trends in the HIV market
• Dovato forecast adjusted higher due to launch trend in the US
• Juluca forecast adjusted higher due to launch trends globally
• Fostemsavir forecast pushed out to align with filing timeframe.

Model updates (7 November 2019)

• Triumeq forecast adjusted higher in the US
• Juluca forecast adjusted lower internationally due to slower initial launch
• Shingrix forecast adjusted higher globally.

Model updates (25 July 2019)

• Advair forecast adjusted higher due to less impact from generics than anticipated
• Anoro Ellipta forecast adjusted lower due to pricing pressure in the US
• Incruse Ellipta forecast adjusted lower due to pricing pressure in the US
• Breo Ellipta forecast adjusted lower due to pricing pressure in the US
• Trelegy Ellipta forecast adjusted higher due to strong uptake
• Tivicay forecast adjusted lower in the US
• Flovent forecast adjusted higher in the US
• Ventolin forecast adjusted higher in the US due to temporary benefit from authorized generic
• Shingrix forecast adjusted higher in the US due to strong demand
• Zejula forecast added
• Dostarlimab forecast added
• Bintrafusp alfa forecast added
• Daprodustat forecast added
• Belantamab mafodotin forecast added
• Otilimab forecast added
• Updated non-pharmaceutical revenue to account for pending GSK and PFE consumer healthcare joint venture, as well as intention to separate the joint venture via a demerger within three years of closing.